Drug Type TCR therapy |
Synonyms- |
Mechanism MAGEA1 inhibitors(Melanoma-associated antigen 1 inhibitors), MAGEA10 inhibitors(Melanoma-associated antigen 10 inhibitors), MAGEA2 inhibitors(MAGE family member A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | SG | 07 Apr 2024 | |
Bladder Cancer | Preclinical | US | 22 Mar 2024 | |
Melanoma | Preclinical | US | 22 Mar 2024 | |
Non-Small Cell Lung Cancer | Preclinical | US | 22 Mar 2024 | |
Recurrent Head and Neck Carcinoma | Preclinical | US | 22 Mar 2024 |